Statin drugs deny prostate cancer cells access to needed hormones, delaying disease progression
the ONA take:
Cholesterol-lowering statin drugs were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT), according to a clinical trial from Dana-Farber Cancer Institute.
In the study, men who had been taking statins since the start of ADT went a median of 27.5 months before experiencing disease progression, compared with 17.4 months for men who were not taking statins.
Laboratory studies focusing on the SLCO2B1 protein found that the protein helps a variety of drugs and hormones enter cells, including both statin drugs and dehydroepiandrosterone sulfate (DHEAS), a precursor of testosterone, the hormone that spurs prostate cancer cell growth.
Using laboratory-grown prostate cancer cell lines, the researchers found that statin drugs monopolized available SLCO2B1 thereby depriving prostate cancer cells of the hormones they need to grow.
The trial involved 926 patients, and 70% of participants experienced disease progression during a 6-year period.
Although this mechanism by which statins may work in prostate cancer can improve patient outcomes, the researchers state that further study is needed to validate their findings.
Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with ADT.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|